

# CERTIFICATE OF ANALYSIS No.: 2024-14007

## CLIENT

Nordic Med Can AB, Eriksgatan 4  
52135 Falköping, Sweden

## SAMPLE \*

Santhica 27 kapselmaterial #2/2024



Sample condition: SUITABLE  
Sample ID: 2407005  
Sample type: Plant material  
Batch No.: \*

Work order: 2024-109967  
Analysis ID: 2024\_056  
Method ID: PHL\_RPC\_16C  
Method SOP: MET-LAB-001-08

Sample received: 12/02/2024  
Start of analysis: 14/02/2024  
End of analysis: 15/02/2024  
Analyst: Valentina Malin

\* Information provided by the client.

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
<b>CBDV</b> - Cannabidivarin	< LOQ	n/a	_____
<b>CBDA</b> - Cannabidiolic acid	< LOQ	n/a	_____
<b>CBGA</b> - Cannabigerolic acid	0.585	0.076	<div style="width: 10%; background-color: #90EE90;">_____</div>
<b>CBG</b> - Cannabigerol	5.67	0.40	<div style="width: 40%; background-color: #808080;">_____</div>
<b>CBD</b> - Cannabidiol	0.209	0.031	<div style="width: 5%; background-color: #90EE90;">_____</div>
<b>THCV</b> - Tetrahydrocannavarin	< LOQ	n/a	_____
<b>CBN</b> - Cannabinol	< LOQ	n/a	_____
<b>Δ<sup>9</sup>-THC</b> - Δ-9-Tetrahydrocannabinol	< LOQ	n/a	_____
<b>Δ<sup>8</sup>-THC</b> - Δ-8-Tetrahydrocannabinol	< LOQ	n/a	_____
<b>CBL</b> - Cannabicyclol	< LOQ	n/a	_____
<b>CBC</b> - Cannabichromene	0.155	0.026	<div style="width: 3%; background-color: #90EE90;">_____</div>
<b>Δ<sup>9</sup>-THCA</b> - Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	_____
<b>CBV</b> - Cannabivarin	< LOQ	n/a	_____
<b>CBCA</b> - Cannabichromenic acid	< LOQ	n/a	_____
<b>CBT</b> - Cannabicitran	0.055	0.012	<div style="width: 1%; background-color: #90EE90;">_____</div>
<b>CBE</b> - Cannabielsoin	< LOQ #	n/a	_____

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor  $k = 2$ , corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

15/02/2024

Approved by:



mag. Janja Ahej  
Analytical Laboratory Manager

Authorized by:



dr. Boštjan Jančar  
Chief Technology Officer

End of Certificate